GLP-1 Hair Loss: Causes, Regrowth and What to Do
Finding more hair in your brush while taking Ozempic, Wegovy or Zepbound can make an otherwise helpful treatment feel unsettling. GLP-1 hair loss is a real concern, but the timing alone cannot tell you whether you have temporary shedding, a nutritional problem or another type of thinning.
Here is what current labels and research show, what recovery can look like, and how to get a useful assessment before changing your medication or buying a hair supplement.
Editorial details
Why can GLP-1 medications cause hair loss?
A major change in weight or nutrition can shift more hairs into their resting phase, so extra shedding appears later. This is one explanation for hair loss during semaglutide or tirzepatide treatment. It does not mean that every shed hair represents permanent follicle damage.
The weight change
Substantial or rapid weight loss can act as a physical stressor, even when losing weight is beneficial for your health.
The food change
A smaller appetite, nausea or restricted eating can make it harder to get enough protein and other nutrients.
Another hair condition
Pattern hair loss can coexist with shedding. Thyroid disease, iron deficiency, illness and other medicines may also need consideration.
The AAD identifies weight loss and reduced nutrient intake as plausible contributors while acknowledging a possible direct drug effect. A 2026 review found that telogen effluvium and androgenetic alopecia, or pattern hair loss, were the main reported subtypes when studies identified a diagnosis. Many reports did not. AAD explanation; Gupta and colleagues, 2026.
“Ozempic hair” is a nickname, not a diagnosis. Semaglutide is used in Ozempic and Wegovy; tirzepatide is used in Mounjaro and Zepbound. Tirzepatide acts on both GIP and GLP-1 receptors. Brand, dose, indication and study population matter when interpreting a risk number.
How common is hair loss with Wegovy or Zepbound?
In the adult weight-management trials below, hair loss was reported by about 3 to 6 people in every 100 receiving treatment, compared with about 1 in 100 receiving placebo. Most participants did not report it. These are trial reports, not a prediction of your personal risk.
| Injection and study group | With treatment | With placebo |
|---|---|---|
| Wegovy 2.4 mg weekly, pooled adult weight-reduction studies | 3.3% | 1% |
| Wegovy 7.2 mg weekly, separate adult trials | 5.8% | 1% |
| Zepbound 5 / 10 / 15 mg weekly, pooled adult studies | 5% / 4% / 5% | 1% |
Sources: Wegovy label, section 6.1 and Zepbound label, section 6.1. The 2.4 mg comparison arm in the 7.2 mg Wegovy trials also reported 3.3%. These injection figures should not be relabeled as Ozempic, Mounjaro or oral-tablet rates. Separate trials cannot establish which drug is kinder to hair.
Women reported hair loss more often than men in both labels. For example, pooled Zepbound reports were 7.1% in women and 0.5% in men, versus 1.3% and 0% with placebo. That difference does not identify the cause of an individual woman’s thinning.
What newer studies add
A 2026 meta-analysis combined nine interventional studies involving 4,114 GLP-1 users. Hair loss was more frequent than with placebo: pooled relative risk 3.25, with a wide 95% confidence interval of 1.44 to 7.36. Its pooled event rate was 3.9%. The relative risk compares groups; 3.9% is the pooled proportion who reported hair loss. Cheng and Chang, 2026.
A separate 2026 study used diabetes-care records to compare people starting GLP-1 medicines with people starting other diabetes treatments. Penn Medicine reports relative increases of 37% versus SGLT2 inhibitors and 68% versus DPP4 inhibitors. This observational finding supports taking the concern seriously, but cannot isolate a direct drug effect from weight change and other differences between patients. Penn Medicine’s report of the BMJ study.
The useful conclusion is narrower than either “the drug definitely damages hair” or “it is only the weight loss”: there is an association, and the cause still needs to be assessed.
When does GLP-1 hair shedding start, and will it grow back?
Telogen effluvium often starts roughly three months after a trigger, and its shedding phase commonly lasts three to six months. Fullness can take longer to return. These are general hair-cycle expectations, not a timetable proven for every GLP-1 user. British Association of Dermatologists.
1. A trigger happens
Weight, food intake, health or medication changes. Shedding may not increase immediately.
2. Shedding becomes noticeable
Often around three months later, more hair appears during washing or brushing. Look back beyond your most recent injection.
3. Shedding settles before fullness returns
After the trigger resolves, density can take additional months to recover. Continuing triggers or another diagnosis can prolong the problem.
For uncomplicated telogen effluvium, regrowth is generally expected. But waiting alone may leave coexisting pattern hair loss untreated. Persistent loss beyond six months, an enlarging part or a receding hairline deserves reassessment. Recovery and overlapping diagnoses.
What does the pattern tell you?
- More shedding across the scalp: compatible with telogen effluvium, especially after a major change.
- A gradually widening part, thinning crown or receding hairline: raises the possibility of pattern hair loss, including thinning made more visible by shedding.
- Distinct patches, inflamed skin or broken hairs: needs an examination rather than an assumption that this is routine weight-loss shedding.
These are clues, not a home diagnostic test. Our guide to hair thinning in women explains why the pattern and medical history matter. 2026 evidence review; AAD: signs and symptoms.
How can you reduce hair loss while taking a GLP-1?
Address a possible trigger and get the diagnosis right before adding hair-growth products. There is no established supplement or routine that guarantees prevention of GLP-1-associated shedding. A useful plan has four parts.
1. Make eating enough part of the treatment plan
Tell your prescriber if nausea, early fullness or food aversions are making regular meals difficult. Ask for a realistic protein and nutrition plan, with a registered dietitian if needed. A short food record can reveal skipped meals or whole food groups that have disappeared from your routine.
Include protein-containing foods you tolerate, such as eggs, yogurt, beans, tofu, fish or poultry, rather than trying to solve reduced intake with a hair gummy. The 2025 joint nutrition advisory emphasizes managing digestive side effects and preventing nutrient deficiencies during GLP-1 treatment. Your nutrition needs depend on your health and intake; more protein is not a proven stand-alone cure for shedding. Four-society nutrition advisory.
2. Ask whether testing is useful for you
A provider may consider blood counts, iron status or thyroid testing based on your history and examination. Other tests depend on the circumstances. Bring up heavy periods, restrictive eating, recent illness and other symptoms rather than ordering a large panel because it is marketed for hair loss. DermNet: telogen effluvium assessment.
Replace a deficiency when one is found. Taking extra iron, zinc or biotin when you do not need it is not a shortcut to regrowth and can cause harm. Tell the provider about every supplement you take. AAD treatment guidance.
3. Review the pace and tolerability of treatment
Ask whether your weight change and food intake fit the intended plan, especially after a dose increase. The answer may involve nutrition support, treatment of side effects or a medication review. It should be a decision with your prescriber, not a dose adjustment made from a hair-loss percentage.
4. Protect the hair you still have
Use gentle washing and detangling, ease off tight styles and minimize heat or harsh chemical processing. These steps reduce avoidable breakage and pulling; they do not switch off shedding from inside the hair cycle. Compare photos taken in the same light and with the same part instead of counting every hair in the drain. AAD hair-care advice.
Should you stop Ozempic, Wegovy or Zepbound because of hair loss?
Do not stop, lower or switch your prescription without discussing the change with your prescriber. Hair loss matters, but so do the reasons you were prescribed treatment and its benefits for your health.
Ask two separate questions: “What type of hair loss do I have?” and “Does my medication plan need to change?” They may have different answers. Treating iron deficiency or pattern hair loss is different from deciding that a drug is no longer tolerable.
There is no reliable head-to-head evidence that switching between semaglutide and tirzepatide will stop shedding. And stopping a trigger does not instantly reverse hairs already entering the resting phase. Agree on a follow-up date and what would justify a change, rather than waiting indefinitely or stopping in frustration. Evidence and remaining uncertainties; Hair-cycle recovery.
Does minoxidil help with GLP-1 hair loss?
Minoxidil may be worth discussing when pattern hair loss is present; it is not automatically needed for a temporary shedding episode. A diagnosis helps you decide whether a continuing treatment commitment makes sense. Evidence for minoxidil in pattern hair loss should not be presented as proof that it prevents GLP-1-related shedding. AAD: diagnosis and treatment.
If it is recommended, ask about the formulation, side effects, expected review date and what happens when you stop. Topical minoxidil can cause an early shed or scalp irritation, and oral minoxidil has a different safety profile. See oral versus topical minoxidil, shedding after starting minoxidil and ongoing minoxidil costs.
What should you bring to a hair-loss review?
A timeline and a few consistent photos are more useful than a bag of new supplements. Keep these details in your own notes or your clinic’s secure system:
- Medication: exact brand or preparation, dose, starting date and dose-change dates.
- Body and diet changes: weight trend, appetite, meals you struggle to eat and digestive symptoms.
- Hair changes: when shedding began, whether loss is widespread or patterned, and scalp symptoms.
- Other possible triggers: illness, surgery, childbirth, major stress and changes to medicines or supplements.
- Photos: the part, temples and crown in comparable lighting, including any pictures from before treatment.
Ask: “Does this look like telogen effluvium, pattern loss or both? Are tests needed? What can we address now? When should we reassess if shedding continues?” Before leaving, know who will review the hair loss and who will manage the GLP-1 prescription.
GLP-1 hair loss: common questions
Is GLP-1 hair loss permanent?
Temporary telogen effluvium usually recovers, but not all loss during treatment is telogen effluvium. A gradually widening part, a receding hairline or continuing loss needs assessment for another or overlapping condition.
Can my hair grow back while I am still taking the medication?
Yes, it is possible, particularly if temporary shedding settles as weight and nutrition stabilize. This is an expectation based on the course of telogen effluvium, not a guaranteed outcome established by GLP-1 trials. Have your prescriber and dermatologist assess the cause and follow recovery before changing treatment. Telogen effluvium recovery; AAD guidance on continuing care.
Does Ozempic cause the same hair loss as Wegovy?
Both contain semaglutide, but doses and study populations differ. The Wegovy injection percentages above are not an Ozempic-specific risk estimate; report new shedding on either medicine and have the cause checked.
Can you have hair loss on a GLP-1 without losing much weight?
Yes, the timing can coincide even without major weight loss, and that makes it especially important to consider other causes. Current research has not established a weight-loss threshold that explains or predicts every case.
Which vitamins prevent hair loss from GLP-1 treatment?
No vitamin has been established as a reliable preventive treatment. A provider may recommend nutrition support or replacement of a documented deficiency, but taking high-dose hair supplements without a reason can create new problems. If you are still comparing products, our hair growth supplements guide explains which ones have evidence. AAD supplement guidance.
Is there a shampoo that stops Ozempic hair loss?
A shampoo cannot correct a medication-related trigger, inadequate nutrition or pattern hair loss. Gentle care can help limit breakage; itching or flaking may need a separate scalp diagnosis rather than a generic “hair growth” shampoo. AAD self-care guidance.
Can women and men both lose hair on Zepbound?
Yes. The Zepbound trials reported hair loss in both, with more reports among women. Those group differences do not mean men are protected or that every woman’s shedding is caused by the medicine.
Should I start minoxidil before taking a GLP-1?
Not automatically. If you already have thinning, ask a dermatologist to identify its cause and discuss whether treatment should begin or continue; starting minoxidil solely as GLP-1 hair-loss prevention is not an established strategy.
How will I know whether my hair is recovering?
Look for less shedding over time and improving fullness in comparable photos, rather than an immediate change after one dose or meal. Agree on a review point with your provider; continuing or changing loss deserves another look.
Sources and editorial notes
We checked current U.S. prescribing information, published research and dermatology guidance on November 9, 2026. Trial reports, observational associations and general hair-care advice are identified separately. This guide is educational, not a diagnosis or an instruction to change treatment. Clinical review is pending. The cover is an editorial illustration; no patient result is shown.
View all 12 sources
- Wegovy U.S. prescribing information: adult injection hair-loss reports, dose-specific comparisons and patient advice.
- Zepbound U.S. prescribing information: adult trial rates, sex differences and safety information.
- Cheng and Chang, 2026 systematic review and meta-analysis: nine interventional studies, pooled risk and event rate.
- Gupta and colleagues, 2026 systematic review: reported hair-loss subtypes, possible mechanisms and limitations.
- Penn Medicine’s report of the 2026 BMJ study: diabetes-care comparisons and the authors’ explanation of causal uncertainty. The full BMJ article was not accessible during our check.
- AAD: GLP-1 effects on skin, hair and nails: potential contributors and coordinating dermatology care.
- British Association of Dermatologists: telogen effluvium: delayed onset, usual course and overlapping pattern hair loss.
- DermNet: telogen effluvium: clinical assessment, triggers and recovery.
- 2025 joint nutrition advisory: nutritional priorities during GLP-1 treatment from four professional societies.
- AAD: hair-loss diagnosis and treatment: diagnosis-led treatment and appropriate supplement use.
- AAD: hair-loss signs and symptoms: patterns and scalp changes that warrant attention.
- AAD: hair-loss self-care: gentle styling and reducing avoidable hair damage.